FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2009681027> ?p ?o ?g. }

• W2009681027 endingPage "32" @default.
• W2009681027 startingPage "20" @default.
• W2009681027 abstract "AMP‐activated protein kinase (AMPK) is activated under conditions that deplete cellular ATP levels and elevate AMP levels. We have recently shown that AMPK can represent a valid target for improving the medical treatment of growth hormone (GH)‐secreting pituitary adenomas and the effects of its activation or inhibition in pituitary tumour cells are worthy of further characterisation. We aimed to determine whether AMPK may have a role in combined antiproliferative therapies based on multiple drugs targeting cell anabolic functions at different levels in pituitary tumour cells to overcome the risk of cell growth escape phenomena. Accordingly, we tried to determine whether a rationale exists in combining compounds activating AMPK with compounds targeting the phosphatidylinositol‐3‐kinase (PI3K)/Akt/ mTOR /p70S6K signalling pathway. AMPK down‐regulation by specific small‐interfering RNAs confirmed that activated AMPK had a role in restraining growth of GH3 cells. Hence, we compared the effects of compounds directly targeting the mTOR ‐p70S6K axis, namely the mTOR inhibitor rapamycin and the p70S6K inhibitor PF‐4708671, with the effects of the AMPK activator 5‐aminoimidazole‐4‐carboxamide ribonucleoside (AICAR) on cell signalling and cell growth, in rat pituitary GH3 cells. AICAR was able to reduce growth factor‐induced p70S6K activity, as shown by the decrease of phospho‐p70S6K levels. However, it was far less effective than rapamycin and PF‐4708671. We observed significant differences between the growth inhibitory effects of the three compounds in GH3 and GH1 cells. Interestingly, PF‐4708671 was devoid of any effect. AICAR was at least as effective as rapamycin and the co‐treatment was more effective than single treatments. AICAR induced apoptosis of GH3 cells, whereas rapamycin caused preferentially a decrease of cell proliferation. Finally, AICAR and rapamycin differed in their actions on growth factor‐induced extracellular signal regulated kinase 1/2 phosphorylation. In conclusion, the results of the present study suggest the increased efficacy of combined antiproliferative therapies, including rapamycin analogues and AMPK activators in GH‐secreting pituitary tumours, as a result of complementary and only partially overlapping mechanisms of action." @default.
• W2009681027 created "2016-06-24" @default.
• W2009681027 creator A5001047673 @default.
• W2009681027 creator A5007409063 @default.
• W2009681027 creator A5038399658 @default.
• W2009681027 creator A5039478018 @default.
• W2009681027 creator A5048100872 @default.
• W2009681027 creator A5084331112 @default.
• W2009681027 date "2014-12-21" @default.
• W2009681027 modified "2023-10-03" @default.
• W2009681027 title "Role of AMP-Activated Protein Kinase Activators in Antiproliferative Multi-Drug Pituitary Tumour Therapies: Effects of Combined Treatments with Compounds Affecting the mTOR-p70S6 Kinase Axis in Cultured Pituitary Tumour Cells" @default.
• W2009681027 cites W1563676220 @default.
• W2009681027 cites W1975613837 @default.
• W2009681027 cites W1988848089 @default.
• W2009681027 cites W1990278643 @default.
• W2009681027 cites W1992809340 @default.
• W2009681027 cites W2001568034 @default.
• W2009681027 cites W2006215820 @default.
• W2009681027 cites W2011185738 @default.
• W2009681027 cites W2011876955 @default.
• W2009681027 cites W2012980983 @default.
• W2009681027 cites W2013239140 @default.
• W2009681027 cites W2014049239 @default.
• W2009681027 cites W2022948223 @default.
• W2009681027 cites W2028005041 @default.
• W2009681027 cites W2030054621 @default.
• W2009681027 cites W2034500462 @default.
• W2009681027 cites W2041819796 @default.
• W2009681027 cites W2045758709 @default.
• W2009681027 cites W2048501945 @default.
• W2009681027 cites W2055671120 @default.
• W2009681027 cites W2059230614 @default.
• W2009681027 cites W2081598837 @default.
• W2009681027 cites W2095591038 @default.
• W2009681027 cites W2097865950 @default.
• W2009681027 cites W2098697214 @default.
• W2009681027 cites W2104267594 @default.
• W2009681027 cites W2114147584 @default.
• W2009681027 cites W2116305496 @default.
• W2009681027 cites W2121174625 @default.
• W2009681027 cites W2138774501 @default.
• W2009681027 cites W2144626362 @default.
• W2009681027 cites W2145336503 @default.
• W2009681027 cites W2150024614 @default.
• W2009681027 cites W2159620999 @default.
• W2009681027 cites W2160226692 @default.
• W2009681027 cites W2165002727 @default.
• W2009681027 cites W2172290767 @default.
• W2009681027 doi "https://doi.org/10.1111/jne.12231" @default.
• W2009681027 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25323047" @default.
• W2009681027 hasPublicationYear "2014" @default.
• W2009681027 type Work @default.
• W2009681027 sameAs 2009681027 @default.
• W2009681027 citedByCount "12" @default.
• W2009681027 countsByYear W20096810272015 @default.
• W2009681027 countsByYear W20096810272017 @default.
• W2009681027 countsByYear W20096810272018 @default.
• W2009681027 countsByYear W20096810272019 @default.
• W2009681027 countsByYear W20096810272020 @default.
• W2009681027 countsByYear W20096810272021 @default.
• W2009681027 countsByYear W20096810272022 @default.
• W2009681027 crossrefType "journal-article" @default.
• W2009681027 hasAuthorship W2009681027A5001047673 @default.
• W2009681027 hasAuthorship W2009681027A5007409063 @default.
• W2009681027 hasAuthorship W2009681027A5038399658 @default.
• W2009681027 hasAuthorship W2009681027A5039478018 @default.
• W2009681027 hasAuthorship W2009681027A5048100872 @default.
• W2009681027 hasAuthorship W2009681027A5084331112 @default.
• W2009681027 hasConcept C126322002 @default.
• W2009681027 hasConcept C134018914 @default.
• W2009681027 hasConcept C170493617 @default.
• W2009681027 hasConcept C184235292 @default.
• W2009681027 hasConcept C185592680 @default.
• W2009681027 hasConcept C2776780712 @default.
• W2009681027 hasConcept C2777949483 @default.
• W2009681027 hasConcept C2780124434 @default.
• W2009681027 hasConcept C43060935 @default.
• W2009681027 hasConcept C502942594 @default.
• W2009681027 hasConcept C55493867 @default.
• W2009681027 hasConcept C62112901 @default.
• W2009681027 hasConcept C62478195 @default.
• W2009681027 hasConcept C71924100 @default.
• W2009681027 hasConcept C75217442 @default.
• W2009681027 hasConcept C86554907 @default.
• W2009681027 hasConcept C86803240 @default.
• W2009681027 hasConcept C88045685 @default.
• W2009681027 hasConcept C95444343 @default.
• W2009681027 hasConcept C97029542 @default.
• W2009681027 hasConceptScore W2009681027C126322002 @default.
• W2009681027 hasConceptScore W2009681027C134018914 @default.
• W2009681027 hasConceptScore W2009681027C170493617 @default.
• W2009681027 hasConceptScore W2009681027C184235292 @default.
• W2009681027 hasConceptScore W2009681027C185592680 @default.
• W2009681027 hasConceptScore W2009681027C2776780712 @default.
• W2009681027 hasConceptScore W2009681027C2777949483 @default.
• W2009681027 hasConceptScore W2009681027C2780124434 @default.
• W2009681027 hasConceptScore W2009681027C43060935 @default.
• W2009681027 hasConceptScore W2009681027C502942594 @default.

• next